X T L Biopharmaceuticals Earlier Announced Definitive Exclusive Sublicense Agreement With Biossil

On March 4, 2025, XTL Biopharmaceuticals Ltd. (the "Company" or "XTL") announced that it has entered into a definitive Exclusive Sublicense Agreement (the "Agreement") with Biossil Inc., a company incorporated under the laws of Canada ("Biossil"). Pursuant to the Agreement, the Company will grant Biossil, for the term of the Agreement, a royalty-free, exclusive, worldwide perpetual sublicense, with the right to sublicense through multiple tiers, to its novel synthetic peptide, hCDR1, including the patent applications and provisional applications and the resulting patents listed in the Agreement and all know-how including all clinical and pre-clinical data related to the product called Edratide (the "Product"), trademarks, trade names, logos and labelling owned or controlled by the Company or its affiliates that is necessary or useful for the research, development, manufacture and/or commercialization of the Product. In consideration for granting the rights under the Agreement the Company will be entitled to cumulative payments of up to approximately US$11,500,000. At closing, Biossil paid US$137,500 as license issuing fee and up to cumulative US$3,362,000 will be due upon the occurrence of certain regulatory milestones and up to cumulative US$ 8,000,000 will be due upon the occurrence of certain commercial milestones, all as determined therein.